Comparison of the Immunogenicity of Cell Culture-Based and Recombinant Quadrivalent Influenza Vaccines to Conventional Egg-Based Quadrivalent Influenza Vaccines Among Healthcare Personnel Aged 18-64 Years: A Randomized Open-Label Trial

被引：27

作者：

Dawood, Fatimah S. ^{[1
]}

Naleway, Allison L. ^{[2
]}

Flannery, Brendan ^{[1
]}

Levine, Min Z. ^{[1
]}

Murthy, Kempapura ^{[3
]}

Sambhara, Suryaprakash ^{[1
]}

Gangappa, Shivaprakash ^{[1
]}

Edwards, Laura ^{[4
]}

Ball, Sarah ^{[4
,5
]}

Grant, Lauren ^{[1
]}

Belongia, Edward ^{[6
]}

Bounds, Kelsey ^{[3
]}

Cao, Weiping ^{[1
]}

Gross, F. Liaini ^{[1
]}

Groom, Holly ^{[2
]}

Fry, Alicia M. ^{[1
]}

Hunt, Danielle Rentz ^{[4
]}

Jeddy, Zuha ^{[4
]}

Mishina, Margarita ^{[1
]}

Kim, Sara S. ^{[1
]}

Wesley, Meredith G. ^{[1
,4
]}

Spencer, Sarah ^{[1
]}

Thompson, Mark G. ^{[1
]}

Gaglani, Manjusha ^{[3
]}

机构：

[1] Ctr Dis Control & Prevent, Atlanta, GA 30329 USA

[2] Kaiser Permanente Northwest, Ctr Hlth Res, Portland, OR USA

[3] Texas A&M Univ, Coll Med, Baylor Scott & White Hlth, Temple, TX USA

[4] Abt Associates Inc, Atlanta, GA USA

[5] Westat Corp, Rockville, MD USA

[6] Marshfield Clin Res Inst, Marshfield, WI USA

来源：

CLINICAL INFECTIOUS DISEASES | 2021年 / 73卷 / 11期

关键词：

influenza vaccines; immunogenicity; healthcare personnel; COVID-19; cohort studies; ADULTS; 65; HEMAGGLUTININ; EFFICACY; VIRUSES;

D O I：

10.1093/cid/ciab566

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Background. RIV4 and cell-culture based inactivated influenza vaccine (ccIIV4) have not been compared to egg-based IIV4 in healthcare personnel, a population with frequent influenza vaccination that may blunt vaccine immune responses over time. We conducted a randomized trial among healthcare personnel (HCP) aged 18-64 years to compare humoral immune responses to ccIIV4 and RIV4 to IIV4. Methods. During the 2018-2019 season, participants were randomized to receive ccIIV4, RIV4, or IIV4 and had serum samples collected prevaccination, 1 and 6 months postvaccination. Serum samples were tested by hemagglutination inhibition (HI) for influenza A/H1N1, B/Yamagata, and B/Victoria and microneutralization (MN) for A/H3N2 against cell-grown vaccine reference viruses. Primary outcomes at 1 month were seroconversion rate (SCR), geometric mean titers (GMT), GMT ratio, and mean fold rise (MFR) in the intention-to-treat population. Results. In total, 727 participants were included (283 ccIIV4, 202 RIV4, and 242 IIV4). At 1 month, responses to ccIIV4 were similar to IIV4 by SCR, GMT, GMT ratio, and MFR. RIV4 induced higher SCRs, GMTs, and MFRs than IIV4 against A/H1N1, A/H3N2, and B/Yamagata. The GMT ratio of RIV4 to egg-based vaccines was 1.5 (95% confidence interval [CI] 1.2-1.9) for A/H1N1, 3.0 (95% CI: 2.4-3.7) for A/H3N2, 1.1 (95% CI:.9-1.4) for B/Yamagata, and 1.1 (95% CI:.9-1.3) for B/Victoria. At 6 months, ccIIV4 recipients had similar GMTs to IIV4, whereas RIV4 recipients had higher GMTs against A/H3N2 and B/Yamagata. Conclusions. RIV4 resulted in improved antibody responses by HI and MN compared to egg-based vaccines against 3 of 4 cell-grown vaccine strains 1 month postvaccination, suggesting a possible additional benefit from RIV4.

引用

页码：1973 / 1981

页数：9

共 28 条

[1] Evaluation of the safety, reactogenicity and immunogenicity of FluBlok® trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy adults 50-64 years of age [J].